Avoid Traditional Muscle Relaxants in CKD—They Are Not Safe First-Line Options
In patients with chronic kidney disease, traditional "muscle relaxants" (cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, metaxalone, orphenadrine) should be avoided entirely, as they carry high risk of CNS adverse effects, lack efficacy in chronic pain, and do not actually relax skeletal muscle 1, 2. Baclofen, though sometimes used for spasticity, is contraindicated in moderate-to-severe CKD due to significant neurotoxicity risk from renal accumulation 3, 4.
The Evidence Against Traditional Muscle Relaxants in CKD
The 2019 AGS Beers Criteria explicitly lists all traditional muscle relaxants (cyclobenzaprine, methocarbamol, carisoprodol, chlorzoxazone, metaxalone, orphenadrine) as potentially inappropriate medications in older adults due to increased risk of sedation, falls, fractures, and cognitive impairment 1. This recommendation carries strong strength with moderate quality evidence.
More critically, a 2020 JAGS guideline on adjuvant analgesics emphasizes that these so-called "muscle relaxants" have no evidence of efficacy in chronic pain and are only approved for acute musculoskeletal pain 2. Given the potential for adverse effects in older adults—a population that overlaps significantly with CKD patients—these drugs are explicitly not favored for chronic pain management.
Baclofen: A Dangerous Option in Renal Impairment
While baclofen (a GABA-B agonist) is sometimes considered for spasticity, it poses severe risks in CKD:
- Baclofen is primarily renally excreted, and its half-life is dramatically prolonged in renal impairment 3, 4
- Case reports document neurotoxicity, myoclonus, altered mentation, seizures, respiratory depression, and hemodynamic instability even at normal doses in CKD patients 3, 4
- Expert recommendation: reduce dose when eGFR is 30-60 mL/min/1.73m² and avoid entirely when eGFR <30 mL/min/1.73m² or on dialysis 3
- Current evidence shows baclofen toxicity occurs at a low threshold in CKD, with no established consensus on safe dosing 4
What to Use Instead
For chronic musculoskeletal pain in CKD patients:
- First-line: Physical therapy, topical NSAIDs (if appropriate), acetaminophen (dose-adjusted for severe CKD)
- Second-line: Consider duloxetine or other SNRIs for chronic pain (these have evidence for musculoskeletal conditions like chronic low back pain and fibromyalgia) 2
- Neuropathic component: Gabapentin or pregabalin with appropriate renal dose adjustment 2
For acute muscle spasm:
- Non-pharmacologic approaches (heat, ice, physical therapy) should be prioritized
- If pharmacotherapy is absolutely necessary, use the lowest effective dose for the shortest duration, recognizing all options carry risk
Critical Pitfalls to Avoid
Do not prescribe cyclobenzaprine, methocarbamol, or carisoprodol thinking they are "safer" muscle relaxants—they all carry significant CNS toxicity risk and lack chronic efficacy 1, 2
Do not use baclofen without checking renal function first—even "normal" doses can cause severe neurotoxicity in CKD 3, 4
Do not assume muscle relaxants work for chronic pain—evidence supports their use only in acute settings, and even then, efficacy is questionable 2
Recognize that CKD patients often have overlapping geriatric vulnerabilities (falls risk, polypharmacy, cognitive impairment) that make CNS-active drugs particularly hazardous 1
The safest approach is to avoid traditional muscle relaxants entirely in CKD patients and instead use evidence-based alternatives like duloxetine for chronic musculoskeletal pain, with appropriate non-pharmacologic interventions as the foundation of care.